3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Ovarian Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Bevacizumab
3
pralsetinib
2
pembrolizumab
2
osimertinib
2
contrast agent BR1
2
Pemetrexed
2
Oncolytic Virotherapy
2
Carboplatin
2
vorasidenib
1
interferon gamma-1b
1
Paclitaxel
1
Microbubbles
1
Interferon-gamma
1
Immunotherapy
1
Gemcitabine
1
Cisplatin
1
Antibodies, Monoclonal
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Nerve Tissue
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled